Applying sequential surveillance methods that use regression adjustment or weighting to control confounding in a multisite, rare-event, distributed setting: Part 2 in-depth example of a reanalysis of the measles-mumps-rubella-varicella combination vaccine and seizure risk
- PMID: 31055178
- DOI: 10.1016/j.jclinepi.2019.04.019
Applying sequential surveillance methods that use regression adjustment or weighting to control confounding in a multisite, rare-event, distributed setting: Part 2 in-depth example of a reanalysis of the measles-mumps-rubella-varicella combination vaccine and seizure risk
Abstract
Objective: In-depth example of two new group sequential methods for postmarket safety monitoring of new medical products.
Study design and setting: Existing trial-based group sequential approaches have been extended to adjust for confounders, accommodate rare events, and address privacy-related constraints on data sharing. Most adaptations have involved design-based confounder strategies, for example, self-controlled or exposure matching, while analysis-based approaches like regression and weighting have received less attention. We describe the methodology of two new group sequential approaches that use analysis-based confounder adjustment (GS GEE) and weighting (GS IPTW). Using data from the Food and Drug Administration's Sentinel network, we apply both methods in the context of a known positive association: the measles-mumps-rubella-varicella vaccine and seizure risk in infants.
Results: Estimates from both new approaches were similar and comparable to prior studies using design-based methods to address confounding. The time to detection of a safety signal was considerably shorter for GS IPTW, which estimates a risk difference, compared to GS GEE, which provides relative estimates of excess risk.
Conclusion: Future group sequential safety surveillance efforts should consider analysis-based confounder adjustment techniques that evaluate safety signals on the risk difference scale to achieve greater statistical power and more timely results.
Keywords: Active surveillance; Distributed databases; Electronic health record (EHR); Group sequential analysis; Rare events; Vaccine safety.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.JAMA Pediatr. 2017 Oct 1;171(10):992-998. doi: 10.1001/jamapediatrics.2017.1965. JAMA Pediatr. 2017. PMID: 28806450 Free PMC article.
-
Combination measles-mumps-rubella-varicella vaccination and the risk of febrile seizure.CMAJ. 2014 Aug 5;186(11):812-3. doi: 10.1503/cmaj.140778. Epub 2014 Jun 30. CMAJ. 2014. PMID: 24982299 Free PMC article. No abstract available.
-
Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12. MMWR Recomm Rep. 2010. PMID: 20448530
-
A combination vaccine against measles, mumps, rubella and varicella.Drugs Today (Barc). 2008 Apr;44(4):279-92. doi: 10.1358/dot.2008.44.4.1210755. Drugs Today (Barc). 2008. PMID: 18536786 Review.
-
Varicella vaccines and measles, mumps, rubella, and varicella vaccine.J Pediatr (Rio J). 2006 Jul;82(3 Suppl):S101-8. doi: 10.2223/JPED.1496. J Pediatr (Rio J). 2006. PMID: 16826308 Review.
Cited by
-
Privacy-preserving estimation of an optimal individualized treatment rule: a case study in maximizing time to severe depression-related outcomes.Lifetime Data Anal. 2022 Jul;28(3):512-542. doi: 10.1007/s10985-022-09554-8. Epub 2022 May 2. Lifetime Data Anal. 2022. PMID: 35499604 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical